Literature DB >> 30377723

Outcome of Self-Expanding Metal Stents in the Treatment of Anastomotic Leaks After Ivor Lewis Esophagectomy.

Patrick Sven Plum1, Till Herbold2, Felix Berlth1, Hildegard Christ3, Hakan Alakus1, Marc Bludau1, De-Hua Chang4, Christiane Josephine Bruns1, Arnulf Heinrich Hölscher5, Seung-Hun Chon6.   

Abstract

BACKGROUND: Esophageal anastomotic leakages after Ivor Lewis esophagectomy are severe and life-threatening complications. We analyzed the outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy.
METHODS: Seventy patients with esophageal anastomotic leakage after Ivor Lewis esophagectomy for esophageal cancer who had received SEMS treatment between January 2006 and December 2015 at our clinic were identified in this retrospective study. The patients were analyzed according to demographic characteristics, risk factors, leakage characteristics, stent characteristics, stent-related complications, sealing success rate and mortality.
RESULTS: Over a 10-year period, 70 patients received SEMS as treatment for postoperative anastomotic leakage after esophagectomy. Technical success of esophageal stenting in anastomotic leakage was achieved in 50 out of 70 cases (71.4%). Sealing success rate was 70% (n = 49) with a median treatment of 28 days (range 7-87). In 20 patients (28.6%), stent-related complications, such as stenosis, dislocation, leakage persistence, perforation or esophagotracheal fistula occurred after the SEMS treatment. Sixty-one patients (87.1%) survived SEMS treatment of esophagogastric anastomotic leakage. Mean follow-up for all patients was 38 months (IQR 10-76), and no significant difference was found in a comparison of the long-term survival rate between patients with successful and unsuccessful SEMS treatment.
CONCLUSIONS: The management of esophageal anastomotic leaks after Ivor Lewis esophagectomy with SEMS is effective, safe and technically feasible. Aggressive non-surgical management should be considered when developing a treatment plan for stenting.

Entities:  

Mesh:

Year:  2019        PMID: 30377723     DOI: 10.1007/s00268-018-4832-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  6 in total

1.  Author's Reply: Outcome of Self-Expanding Metal Stents in the Treatment of Anastomotic Leaks After Ivor Lewis Esophagectomy.

Authors:  Patrick Sven Plum; Felix Berlth; Till Herbold; Seung-Hun Chon
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

2.  Letter to the Editor: Outcome of Self-Expanding Metal Stents in the Treatment of Anastomotic Leaks After Ivor Lewis Esophagectomy.

Authors:  Victor D Plat; Freek Daams; Donald L van der Peet
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

Review 3.  Critical Appraisal of the Impact of Oesophageal Stents in the Management of Oesophageal Anastomotic Leaks and Benign Oesophageal Perforations: An Updated Systematic Review.

Authors:  Sivesh K Kamarajah; James Bundred; Gary Spence; Andrew Kennedy; Bobby V M Dasari; Ewen A Griffiths
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

4.  A Novel Hybrid Stent with Endoscopic Vacuum Therapy for Treating Leaks of the Upper Gastrointestinal Tract.

Authors:  Seung-Hun Chon; Ulrich Töx; Florian Lorenz; Isabel Rieck; Britta Janina Wagner; Robert Kleinert; Hans Friedrich Fuchs; Tobias Goeser; Alexander Quaas; Christiane J Bruns
Journal:  Visc Med       Date:  2020-12-01

5.  Outcome of endoscopic vacuum therapy for duodenal perforation.

Authors:  Mickael Chevallay; Florian Lorenz; Philippe Bichard; Jean-Louis Frossard; Thomas Schmidt; Tobias Goeser; Christiane Josephine Bruns; Stefan P Mönig; Seung-Hun Chon
Journal:  Surg Endosc       Date:  2022-10-14       Impact factor: 3.453

6.  Endoscopic vacuum therapy versus stent treatment of esophageal anastomotic leaks (ESOLEAK): study protocol for a prospective randomized phase 2 trial.

Authors:  Michael Tachezy; Seung-Hun Chon; Isabel Rieck; Marcus Kantowski; Hildegard Christ; Karl Karstens; Florian Gebauer; Tobias Goeser; Thomas Rösch; Jakob R Izbicki; Christiane J Bruns
Journal:  Trials       Date:  2021-06-02       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.